Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock

CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common stock. The gross proceeds to Editas Medicine from this offering are expected to be approximately $50 million, before deducting estimated offering expenses. Editas Medicine has granted the underwriter a 30-day option to purchase up to an additional 295,500 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine.

Morgan Stanley is acting as sole book running manager for the offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-216444), which was declared effective by the Securities and Exchange Commission (SEC) on March 15, 2017. The offering is being made only by means of a prospectus supplement and the accompanying prospectus. A final prospectus supplement relating to the offering will be filed with the SEC and will be available at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Editas Medicine

Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

1 2 3
View single page >> |

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Michael Molman 2 years ago Contributor's comment

Looking forward to hearing more information about $EDIT. Company seems to operate in a very exiting and potentially fast growing new field.